Recent studies have highlighted the potential of kidney-related medications in treating heart conditions. A trial led by researchers at Mount Sinai demonstrated that empagliflozin, a drug for kidney diseases, can safely reduce heart failure episodes in acute myocardial infarction patients, irrespective of their renal function. Another study found that finerenone, used for chronic kidney disease, may lower cardiovascular death risks in heart failure patients with mildly reduced or preserved ejection fraction. Bayer's kidney drug, Kerendia, was shown to reduce the risk of death and serious events in patients with a common form of heart failure, marking a significant step for the company. Additionally, research into aldesleukin, an anti-inflammatory drug, suggests it could decrease inflammation and the risk of future heart attacks, potentially changing treatment practices for heart attack survivors. These findings collectively underscore the evolving role of kidney medications and anti-inflammatory treatments in cardiovascular health.